Skip to main content
. 2012 Aug 16;6:287–303. doi: 10.4137/CMO.S8511

Figure 5.

Figure 5

Mean difference in BMD from placebo at 36 months, denosumab vs. placebo, in men with prostate cancer receiving ADT: subgroup analyses.127

Notes: Results are presented as least-squares means.